# EDIT — slm-full-gpu

## Metadata

ticker: EDIT
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 78abcc2cd2c550d133990a35ea4650b19b4a39d205f1e89dcd51e80dc41723c6
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 674, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 13.41, "latency_s_total": 13.41, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 514, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.194, "latency_s_total": 11.194, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 132, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.406, "latency_s_total": 4.406, "parse_failure": 0, "prompt_tokens": 632, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 178, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.952, "latency_s_total": 5.952, "parse_failure": 0, "prompt_tokens": 626, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 201, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 6.328, "latency_s_total": 6.328, "parse_failure": 0, "prompt_tokens": 586, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 152, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.516, "latency_s_total": 7.516, "parse_failure": 0, "prompt_tokens": 754, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 992, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.303, "latency_s_total": 11.303, "parse_failure": 0, "prompt_tokens": 1704, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.79,
  "currency": "USD",
  "market_cap": 428488288.0,
  "forward_pe": -3.7045395,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "financial_currency": "USD",
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin_pct": -157.32,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker EDIT, here are the key takeaways regarding the company's financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to fund ongoing operations, research, and development. If unable to raise capital when needed, the company may be forced to delay, reduce, or eliminate research programs or commercialization efforts.
*   **Cash Runway:** Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027.
*   **Limited External Funding Sources:** The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments under a license agreement with Vertex.
*   **Dilution Risks:** Raising additional capital through public or private equity offerings may cause dilution to stockholders, restrict operations, or require the relinquishment of rights to technologies or product candidates.

**Operational Status and Development**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It is expected to be many years, if ever, before a product candidate is ready for commercialization.
*   **Primary Candidate (EDIT-401):** A significant portion of expenses and future activities will focus on the preclinical and clinical development of EDIT-401.
*   **Revenue Timeline:** Commercial revenues are not expected for years, if at all. The company does not expect to generate substantial product revenues until it can successfully identify candidates, complete trials, obtain marketing approval, and commercialize medicines.

**Risk Factors**
*   **Profitability Uncertainty:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Failure to become profitable could decrease the company's value and impair its ability to raise capital or continue operations.
*   **Increasing Expenses:** Expenses are expected to increase significantly due to costs associated with drug discovery, preclinical and clinical trials, regulatory reviews, intellectual property maintenance, and potential commercialization infrastructure.
*   **Regulatory and Economic Risks:** Expenses could exceed expectations if regulatory authorities (such as the FDA or EMA) require additional studies. Additionally, unfavorable national or global economic conditions, political unrest, or financial market volatility could adversely affect the business, demand for products, and the ability to raise capital.
*   **Commercialization Challenges:** Even if products are approved, the company may not achieve commercial success. Success depends on many factors, including the ability to establish manufacturing, sales, and distribution infrastructure, as well as securing healthcare coverage and reimbursement.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Substantial Funding:** The company requires substantial additional funding to support ongoing activities, including the preclinical and clinical development of product candidates like EDIT-401, as well as potential commercialization expenses. If capital cannot be raised when needed, the company may be forced to delay, reduce, or eliminate research and development programs or commercialization efforts.
*   **Limited Committed External Funds:** As of December 31, 2025, the company’s existing cash and cash equivalents are expected to fund operations only into the third quarter of 2027. The only significant committed potential external sources of funds are rights to contingent payments under collaboration agreements with BMS and retained portions of payments under a license agreement with Vertex.
*   **Regulatory and Development Risks:** The company’s most advanced research programs are currently in the preclinical testing stage. Expenses could increase beyond expectations if regulatory authorities require additional studies. Identifying and developing product candidates is time-consuming, expensive, and uncertain, and the company may never generate the necessary data to obtain marketing approval.
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Commercialization Challenges:** Even if products receive marketing approval, the company may not become profitable. Commercial revenues are not expected for years, if ever, and the company may need to establish its own sales, marketing, and distribution infrastructure, incurring significant expenses.
*   **Dilution and Restriction Risks:** Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders, restrict operations, or require the company to relinquish rights to its technologies or product candidates.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.79 with a market capitalization of approximately $428.5 million. The company reported revenue of $47.0 million but faces significant profitability challenges, evidenced by a net loss of $73.9 million and a negative profit margin of -157.32%. Consequently, the forward P/E ratio remains negative at -3.70, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk investment profile typical of early-stage biotechnology firms reliant on future pipeline developments rather than current cash flow.

### Recent Developments

Editas Medicine, Inc. (EDIT) continues to operate as a pre-revenue biotechnology company, with its latest 10-K filing in March 2026 highlighting persistent net losses and a negative profit margin of -157.32%. The company’s financial health remains under pressure, as evidenced by a net income of -$73.95 million against revenues of only $47 million, underscoring the significant cash burn associated with its R&D pipeline. Investors should note the company's explicit risk factors regarding the need for additional capital, which may lead to dilution or operational constraints if funding is not secured. With the stock trading near its 52-week low of $1.66 and currently at $2.79, market sentiment reflects the inherent uncertainties and execution risks detailed in recent SEC filings.

### SEC Filing Highlights
Editas Medicine reported net losses of $160.1 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it remains in the preclinical stage with no commercial revenues. The company’s existing cash runway is projected to fund operations only through the third quarter of 2027, necessitating substantial additional capital to support ongoing R&D and development of its primary candidate, EDIT-401. Management warns that failure to secure funding could force delays or elimination of research programs, while future capital raises may result in significant shareholder dilution. Consequently, the company expects to incur substantial losses for the foreseeable future and may never achieve profitability.

### Risk Factors

*   **Substantial Capital Requirements and Liquidity Constraints:** The company has a history of significant operating losses and an accumulated deficit of $1.6 billion as of December 31, 2025. Current cash reserves are projected to fund operations only through the third quarter of 2027, necessitating additional capital raises that may result in shareholder dilution or restrictive covenants.
*   **High Uncertainty in Clinical Development and Regulatory Approval:** The most advanced product candidates remain in preclinical stages, with no guarantee of successful development or regulatory approval. Failure to generate necessary data or unexpected increases in development costs could severely impair the company’s ability to commercialize products.
*   **Absence of Commercial Revenue and Profitability:** The company has never generated commercial revenue and is not expected to do so for several years, if ever. Even with successful approvals, the company faces significant challenges in establishing sales infrastructure and achieving profitability amidst ongoing high expenses.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a preclinical-stage biotechnology company focused on gene editing, currently trading at $2.79 with a market capitalization of approximately $428.5 million despite reporting a net loss of $73.9 million and an accumulated deficit of $1.6 billion. The stock is notable for its precarious liquidity position, with existing cash reserves projected to fund operations only through the third quarter of 2027, creating immediate pressure for capital raises. The single most important near-term variable is the company’s ability to successfully secure additional financing without excessive dilution while advancing its primary candidate, EDIT-401, through clinical development.

### Outlook
The directional outlook for Editas Medicine is cautiously cautious, defined by the tension between the transformative potential of its gene-editing platform and the severe near-term liquidity constraints. Key variables to monitor include the timing and terms of any necessary capital raises, as well as the progression of clinical data for EDIT-401, which serves as the primary catalyst for re-rating the stock. The thesis would be strengthened by successful clinical milestones that validate the technology and attract strategic partnerships or favorable financing terms, whereas any delays in development or adverse safety signals would significantly weaken the investment case by exacerbating the risk of dilution or program termination. Investors should remain vigilant regarding the company's cash burn rate and its ability to navigate the preclinical-to-clinical transition without compromising operational continuity.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically identify every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections, then evaluate each.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $2.79"
LABEL: SUPPORTED
REASON: The source data explicitly lists `"current_price": 2.79`.

---

CLAIM: "market capitalization of approximately $428.5 million"
LABEL: SUPPORTED
REASON: Source data shows `"market_cap": 428488288.0`, which rounds to approximately $428.5 million.

---

CLAIM: "net loss of $73.9 million"
LABEL: SUPPORTED
REASON: Source data shows `"net_income": -73949000.0`, which is −$73.9 million (rounded to one decimal place).

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "accumulated deficit stood at $1.6 billion" as of December 31, 2025.

---

CLAIM: "existing cash reserves projected to fund operations only through the third quarter of 2027"
LABEL: SUPPORTED
REASON: Both RAG sections and the SEC Filing Highlights pre-written section explicitly state cash is expected to fund operations "into the third quarter of 2027."

---

CLAIM: "primary candidate, EDIT-401, through clinical development"
LABEL: UNSUPPORTED
REASON: The source data (RAG sections and pre-written SEC Filing Highlights) consistently describes EDIT-401 as being in **preclinical** stages, not clinical development; characterizing its advancement as "through clinical development" misrepresents the stage disclosed in the source.

---

**OUTLOOK**

---

CLAIM: "progression of clinical data for EDIT-401"
LABEL: UNSUPPORTED
REASON: All source materials describe EDIT-401 as being in preclinical testing stages; no clinical data or clinical-stage status for EDIT-401 is present in the source data, making a reference to "clinical data" for EDIT-401 unsupported.

---

CLAIM: "preclinical-to-clinical transition"
LABEL: SUPPORTED
REASON: The source data confirms EDIT-401 is in preclinical stages, and the directional framing of a preclinical-to-clinical transition is a direct restatement of the developmental stage disclosed; this is consistent with the source's description of the company as preclinical-stage with future clinical development anticipated.

---

*No additional quantitative figures, price targets, thresholds, ratios, percentages, or named forward-looking numbers appear in the Outlook section beyond those already evaluated above.*
